Jiangsu Yahong Meditech Co. Ltd.
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis … Read more
Jiangsu Yahong Meditech Co. Ltd. (688176) - Total Liabilities
Latest total liabilities as of September 2025: CN¥412.49 Million CNY
Based on the latest financial reports, Jiangsu Yahong Meditech Co. Ltd. (688176) has total liabilities worth CN¥412.49 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Yahong Meditech Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how Jiangsu Yahong Meditech Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Yahong Meditech Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Jiangsu Yahong Meditech Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥3.00 Billion |
|
TVS Holdings Limited
NSE:TVSHLTD
|
India | ₹473.56 Billion |
|
Arctech Solar Holding Co Ltd
SHG:688408
|
China | CN¥5.66 Billion |
|
SeaWorld Entertainment Inc
F:W2L
|
Germany | €3.05 Billion |
|
Purecycle Technologies Holdings Corp
NASDAQ:PCT
|
USA | $920.90 Million |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
China | CN¥11.64 Billion |
|
Omeros Corporation
NASDAQ:OMER
|
USA | $406.18 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Jiangsu Yahong Meditech Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Yahong Meditech Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Yahong Meditech Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of Jiangsu Yahong Meditech Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥252.62 Million | +4.17% |
| 2023-12-31 | CN¥242.50 Million | +135.48% |
| 2022-12-31 | CN¥102.98 Million | +19.78% |
| 2021-12-31 | CN¥85.98 Million | +100.28% |
| 2020-12-31 | CN¥42.93 Million | -2.41% |
| 2019-12-31 | CN¥43.99 Million | +133.20% |
| 2018-12-31 | CN¥18.86 Million | -- |